EX-10.8





 Certain confidential information contained in this document, marked by [**], has been
omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or confidential. 

Exhibit 10.8 
 AMENDMENT
No. 1 
 TO THE SOPHIA GENETICS SA AGREEMENT 

dated January 19, 2018 

(the “Amendment”) 
 effective as
of June 07, 2019 (the “Effective Date”) 
 BY and BETWEEN: 

QIAGEN GmbH, a corporation organized under the laws of Germany having its principal office at [**] (“ QIAGEN”) , and 

Sophia Genetics SA, Rue du Centre 172, CH-1025 Saint-Sulpice, Switzerland a corporation organized under the
laws of the Switzerland (“Sophia Genetics SA”); 
 QIAGEN and Sophia Genetics SA are also referred to as
“Party” or jointly as “Parties”. 
 WHEREAS, the Parties have entered into an agreement dated
January 19, 2018 (the “Agreement” ), according to which QIAGEN sells certain amplification technologies including library amplification kits for Next Generation Sequencing Technologies to Sophia Genetics SA for distribution as
integral part of Sophia Genetics SA’ s molecular biology products; and 
 WHEREAS, the Parties would now like to extend the
scope of the Agreement to include further Goods on the terms set out herein. 
 NOW THEREFORE, the Parties agree as follows: 

1.1. Section 1.4 of the Agreement shall be deleted in its entirety and replaced as follows: 

Purchaser Product The term “Purchaser Product ” shall mean Sophia Genetics’ bundle solutions, combining capture-based
next-generation sequencing assays with SOPHiATM artificial intelligence to enable superior detection of genomic variants. The Purchaser Product will, in addition to the Products, contain
components that are manufactured by a third party. 
 1.2. Schedule A of the Agreement shall be deleted and replaced in
its entirety by the Schedule A as attached to this Amendment. 
 1.3. Schedule B of the Agreement
shall be deleted and replaced in its entirety by the Schedule B as attached to this Amendment. 
  












 1.4. Schedule C of the Agreement shall be deleted and replaced in its
entirety by the Schedule C as attached to this Amendment. 
 1.5. Schedule D of the Agreement
shall be deleted and replaced in its entirety by the Schedule D as attached to this Amendment. 
 1.6. Schedule
E of the Agreement shall be deleted and replaced in its entirety by the Schedule E as attached to this Amendment. 
 2. All other
provisions of the Agreement shall remain unaltered and in force. Definitions in this Amendment shall have the same meaning as in the Agreement unless expressly stated otherwise in this Amendment. 

3. MISCELLANEOUS 
 3.1. Any provision of the
Amendment (including this Section 3) may be amended or waived only if such amendment or waiver is by written instrument executed by each Party and explicitly refers to this Amendment. 

3.2. Should any provision of this Amendment, or any provision incorporated into this Amendment in the future, be or become invalid or
unenforceable, the validity or enforceability of the other provisions of this Amendment shall not be affected thereby. The Parties hereby agree to substitute the invalid or unenforceable provision by a suitable and equitable provision which , to the
extent legally permissible, comes as close as possible to the intent and purpose of the invalid or unenforceable provision. The same shall apply: (i) if the Parties have, unintentionally, failed to address a certain matter in this Amendment; in
this case a suitable and equitable provision shall be deemed to have been agreed upon which comes as close as possible to what the Parties, in the light of the intent and purpose of this Amendment, would have agreed upon if they had considered the
matter; or (ii) if any provision of this Amendment is invalid because of the scope of any time period or performance stipulated herein; in this case the Parties hereby agree to substitute the time period or performance by that which is legally
permissible and comes as close as possible to the stipulated time period or performance. For the avoidance of doubt, any period of limitation shall not be prolonged by sentence 3. 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 In Witness Whereof, the Parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

					
	QIAGEN GmbH
		
	By:	 	 /s/ [ILLEGIBLE]

		 	Name:
		 	 Title: Senior Director Legal Affairs

EMEA




 

					
	By:	 	 /s/ [ILLEGIBLE]

		 	Name:
		 	Title: QIAGEN Finance Department


  

					
	Sophia Genetics SA
		
	By:	 	 /s/ Damien Lapray

		 	Name:	 	Damien Lapray
		 	Title: 	 	CCO
		
	By:	 	 /s/ Valentin Matillon

		 	Name:	 	Valentin Matillon
		 	Title: 	 	CFO



  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 SCHEDULE A: 

LIST OF PRODUCTS 
 The term
“Products” (or “Product”) shall mean the following goods: 
 [**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 SCHEDULE B 

PRICE OF PRODUCTS 
 [**]


  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 SCHEDULE C 

KIT CONTENT 
 [**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 SCHEDULE D 

[**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 EXAMPLE CERTIFICATE OF ANALYSIS 

[**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 EXAMPLE PRODUCT SPECIFICATION FORM 

[**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential. 













 SCHEDULE E 

[**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or
confidential.